Eribulin vs Dacarbazine in Soft Tissue Sarcoma

Patrick Schöffski, MD, of University Hospitals Leuven discusses the phase 3 study comparing eribulin to dacarbazine in patients with liposarcomas or leiomyosarcomas, the 2 most common forms of sarcoma.

Reference
Schöffski P, Maki RG, Italiano A, et al. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol. 2015; 33(suppl; abstr LBA10502).